2022 Development Timelines1AD - 2022 GoalsSignificantprogress...

2022 Development Timelines

1AD - 2022 Goals

Significantprogress anticipated on both existing core programs and further pipelineexpansion

AD-214 – First in class anti-fibrotic

• Inhaledformulation development: nebulisation feasibility, efficacy in animal model ofIPF (Q1); lung distribution imaging in healthy and disease model animals (Q1);dose finding and clinical formulation (Q2)

• Intravenousformulation development (Q3)

• GLP toxicologywith inhaled formulation (commences 2H22)

• Continuing partneringdiscussions (Q1); selection of next indication

GE Healthcare – GZMB PET imaging

• Pre-clinicalproof of concept – milestone payment (mid-22)

Carina Biotech – i-body enabled CAR-T cells

• 1stexperimental results on Target #1

• Commencei-body discovery on Target #2

Internal pipeline and platform development

• Initialfunctional data on i-body binders against internal Target #2 (2H22)

• i-body2.0: newintellectual property filed (end’22)

• 7 programs inpipeline (end’22)

• Additionalpatent filings, grants on individual i-body enabled products